4000 prescriptions a week for Obesity Drug

http://genericpharmalitigator.com/wp-content/uploads/2013/09/wpid-curata__c019090ad1527b5cd8db7f4b4147446a.jpg

Eisai Inc. has developed and marketed drugs to treat breast cancer, epilepsy and Alzheimer’s disease, but its newest product targets a medical condition that has been called America’s fastest growing epidemic – obesity.

This summer, Eisai – pronounced A-zigh – began selling a prescription drug, Belviq, which has been approved as a weight-loss aid. The drug triggers serotonin receptors in the brain to create a sensation of fullness, or satiety in patients, causing them to eat less. The drug is intended only for patients who are obese – with a body mass index of 30 or greater, or overweight, with a body mass index of 27 or higher, and other health risks such as diabetes, high blood pressure or high cholesterol.

The drug went on sale June 7, and the company is averaging about 4,000 prescriptions a week.

 

Read the source article at Life Science Investing News